LSX Biotech Growth CEO Forum


Biotech Growth / Late Growth Stage CEO Forum

Tuesday, June 21 11:15am - 12:45pm
Room 201

Agenda | Hosts | Book

Open to CEO, Founder, Co-Founder, President, Chairman or c-suite executive (CFO, CBO, CCO, CSO, CMO) of US-based, post-series A-funded, therapeutic Biotech companies.

Free to attend, pre-registration only, Chatham House Rule forum where all participants are active discussants. 

  • Benchmark yourself against your peers
  • Uncover key factors of success
  • Share war stories and common challenges
  • Engage in peer-to-peer discussion
  • Make meaningful connections
  • Find new ways to help your business thrive

Agenda

There’s nothing that comes close to hearing the honest advice and experience of peers treading the same path as you. LSX’s CEO Forums offer executives the chance to exchange ideas with and seek advice from peers in a private group setting. They are an opportunity to share learnings, best practice and some great thinking, as well as meeting other influential people to support your business journey. Capped at 20 participants, the forums operate under strict Chatham House Rule.


11:15am Welcome and Introductions


11:20am Future of building biotech .. evolution or revolution

In an ever changing commercial and regulatory landscape do biotech need to adapt their approach to building their business

  • How do you do more with less?
  • Many newly formed biotech’s are being challenged with significant delays due to COVID related issues impacting on financial business plans
  • How to demonstrate value in an evolving landscape with significant economic issues impacting the overall healthcare industry
  • Leveraging innovative pathways to reduce time to approval; are their opportunities to reduce to development time based on lessons learnt from the development pathway for the vaccines and the expedited regulatory review process that many countries and regions may adopt
  • Culture change from R&D to communalization … establish a new co; What are the key changes in the operating model required for a company to sustainably transition from a research focused company to an established biotech.

John Westwood, Partner & Global Life Sciences Business Leader, Oliver Wyman

John Westwood, Partner & Global Life Sciences Business Leader, Oliver Wyman


11:35am Q&A


11:45am Trends in Licensing and Collaborations

This session will cover:

  • Increasing financial terms/inflation
  • Scope of licensed fields of use and exclusivity
  • Anti-stacking provisions
  • Sublicensing revenue and other value sharing
  • Reversion licenses and terms, alternatives to termination
  • Territory specific transactions (e.g., China)

Alan Tamarelli, Partner, Cooley LLP

Alan Tamarelli, Partner, Cooley LLP


12:00pm Q&A


12:10pm The thrills and challenges of building successful growing biotech companies

  • Discuss how to transform novel scientific concepts into drug discovery and development programs, building a strong culture and effective teams
  • Attract the right investors to support the evolution of the company over time for critical growth

Robert Barrow, CEO, MindMed

Robert Barrow, CEO, MindMed


12:25pm General Discussion (suggested topics to include but not limited to)

  • Fundraising challenges and opportunities
  • Overcoming barriers to market and regulatory approval
  • Creating the right deals and partnerships to move your business forward
  • Internationalising and company growth

1:00pm Wrap-up



Co-hosts:

Cooley         Oliver Wyman Logo

 

TICKET OPTIONS